Seven viruses are officially classified as carcinogenic to humans, meaning they can directly cause cancer. Together with a few non-viral infections, these agents account for roughly 2.3 million new cancer cases worldwide each year, about 12% of the global total. Most people infected with these viruses never develop cancer, but chronic or poorly controlled infections raise the risk substantially over time.
How Viruses Cause Cancer
Viruses don’t cause cancer the way cigarettes or radiation do. Instead of damaging DNA directly, oncogenic viruses hijack the cell’s own growth controls. They produce proteins that disable the molecular brakes cells use to prevent uncontrolled division. In a healthy cell, tumor suppressor proteins act as checkpoints, stopping the cell from copying itself when something goes wrong. Viral proteins effectively remove those checkpoints, pushing cells into continuous replication.
HPV offers the clearest example. Two viral proteins disable the cell’s two most important tumor suppressors. One forces cells to skip past their normal growth pause and begin copying DNA prematurely. The other dismantles a backup system that would normally shut down a cell behaving abnormally. With both safeguards gone, infected cells accumulate genetic errors over years or decades, eventually becoming cancerous. Other oncogenic viruses use different strategies, but the core principle is the same: the virus benefits from keeping its host cell alive and dividing, and that sustained, unregulated growth is what tips toward cancer.
Human Papillomavirus (HPV)
HPV is the single largest viral contributor to cancer worldwide. Twelve high-risk strains (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) can cause six types of cancer: cervical, anal, oropharyngeal (back of the throat), penile, vaginal, and vulvar. HPV 16 and 18 are responsible for the majority of these cases.
Most HPV infections clear on their own within a year or two. Cancer develops only when a high-risk strain persists for many years, giving the viral proteins enough time to accumulate the genetic damage described above. This is why cervical screening programs are so effective: they catch precancerous changes years before they become dangerous.
Vaccination has dramatically changed the outlook. In England, women who received the HPV vaccine at ages 12 to 13 had an 84% lower rate of cervical cancer compared to unvaccinated cohorts. The vaccine targets the highest-risk strains and is most effective when given before any exposure to the virus.
Hepatitis B and Hepatitis C
Hepatitis B (HBV) and hepatitis C (HCV) together cause about 85% of all hepatocellular carcinoma, the most common form of liver cancer. HBV accounts for roughly 54% of those cases and HCV for about 31%. Both viruses cause cancer through a similar path: chronic infection leads to ongoing liver inflammation, which over decades produces scarring (cirrhosis) and eventually malignant changes.
HBV can also integrate its DNA directly into liver cells, disrupting genes that control cell growth. HCV works somewhat differently, driving cancer primarily through the sustained cycle of cell damage and repair that comes with chronic inflammation. The risk is highest in people who carry the virus for decades without treatment.
An effective HBV vaccine has existed since the 1980s and is now part of routine childhood immunization in most countries. No vaccine exists for HCV, but antiviral treatments developed in the last decade can cure HCV infection in over 95% of cases, which significantly reduces future liver cancer risk.
Epstein-Barr Virus (EBV)
Epstein-Barr virus is one of the most common viruses on earth. Over 90% of adults carry it, usually acquiring it in childhood or adolescence (it’s the virus behind mononucleosis). For the vast majority of people, EBV causes no long-term problems. But in a small fraction of carriers, it contributes to several cancers.
The strongest link is with nasopharyngeal cancer, a malignancy of the upper throat behind the nose. Latent EBV is found in more than 95% of undifferentiated nasopharyngeal cancer cases regardless of the patient’s geographic origin or ethnicity. EBV is also associated with certain lymphomas, including Burkitt lymphoma (most common in sub-Saharan Africa) and some forms of Hodgkin lymphoma. In people with weakened immune systems, EBV-driven lymphomas become more likely because the body can no longer keep the virus in check.
EBV also plays a role in some stomach cancers. When EBV and the bacterium H. pylori infect the stomach simultaneously, they amplify each other’s damage. Co-infection triggers more severe inflammation and activates signaling pathways that promote tumor growth more aggressively than either pathogen alone. EBV silences certain tumor suppressor genes through a chemical modification process, making the cancer-promoting effects of H. pylori harder for the body to counteract.
Human Herpesvirus 8 (HHV-8)
Also called Kaposi sarcoma-associated herpesvirus, HHV-8 causes Kaposi sarcoma, a cancer that forms in the lining of blood and lymph vessels and often appears as red or purple skin lesions. Before effective HIV treatment became available, Kaposi sarcoma was one of the defining illnesses of AIDS, because HIV-related immune suppression allows HHV-8 to flourish.
Beyond Kaposi sarcoma, HHV-8 causes primary effusion lymphoma and multicentric Castleman disease, both rare but serious conditions. Organ transplant recipients are another high-risk group: among transplant patients with HHV-8 infection tracked by the CDC, 61% developed Kaposi sarcoma and a smaller percentage developed lymphoproliferative disorders. The common thread is immune suppression, whether from HIV, transplant medications, or other causes.
Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)
HTLV-1 is a retrovirus that infects a type of white blood cell called T cells. It spreads through breastfeeding, sexual contact, blood transfusions, and shared needles. An estimated 5 to 10 million people worldwide carry HTLV-1, with the highest rates in Japan, the Caribbean, parts of South America, and sub-Saharan Africa.
The lifetime risk of developing adult T-cell leukemia/lymphoma (ATL) among HTLV-1 carriers is about 5%, according to the World Health Organization. That means 95% of carriers never develop this cancer. But ATL, when it does occur, is aggressive and difficult to treat. The virus typically persists silently for decades before triggering disease, usually in people who were infected early in life through breastfeeding.
Merkel Cell Polyomavirus (MCV)
Merkel cell polyomavirus is the most recently identified cancer-causing virus, discovered in 2008. It causes Merkel cell carcinoma, a rare but aggressive skin cancer that typically appears as a painless, firm lump on sun-exposed areas of the skin, most often in older adults. About 75% of Merkel cell carcinoma cases contain MCV DNA integrated directly into the tumor’s genome.
Like EBV, MCV infection is extremely common and almost always harmless. The virus is widespread in the general population and appears to live quietly on healthy skin. Cancer develops only in rare cases where the virus integrates into a cell’s DNA in a way that locks its growth-promoting proteins in a permanently active state while losing the ability to replicate normally. Immune suppression is again a major risk factor.
Why Most Infections Don’t Lead to Cancer
A common thread across all these viruses is that cancer is a rare outcome of a common infection. Billions of people carry EBV, most sexually active adults encounter HPV at some point, and MCV is nearly universal on human skin. Cancer develops when specific conditions align: the infection persists for years or decades, the immune system fails to keep it controlled, and the virus happens to disrupt the right combination of genes in the right cell type.
This is why immune health matters so much. People with HIV, organ transplant recipients on immunosuppressive drugs, and others with compromised immune systems face significantly higher risks of virus-associated cancers. It’s also why prevention strategies focus on two fronts: vaccines to prevent infection in the first place (HPV and HBV), and screening programs to catch precancerous changes early (cervical Pap tests, liver ultrasounds for hepatitis carriers). For viruses without vaccines, antiviral treatment that controls or clears the infection, as with hepatitis C, lowers cancer risk over time.